FDA indicates proposed double-blind Phase 2/3 design could be considered adequate and well controlled as Merakris prepares its first commercial-pilot GMP drug lot for a potentially pivotal trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results